Apyx Medical Corporation (APYX) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.60 (0.00% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, APYX ranks #970 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.75 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While APYX currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.76) and Max Pain ($2.73) forces dealer call-delta covering toward $5.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Apyx Medical Corporation (APYX) slipped 0.00% to $2.60, trading at 12% of its 52-week range ($2.25 – $5.08). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on APYX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for APYX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Apyx Medical Corporation (APYX) ranks #970 by composite RQD confidence (21/100, grade E) and #638 by equity capitalization ($109.5M). Within this direct 5-issuer industry benchmark cohort, APYX leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with APYX at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APYX
ACTIVE
Apyx Medical Corporation | E | 21/100 | — | 62.5% | -28.9% | 0.00% | $109.5M | Benchmark Subject |
| PYPD PolyPid Ltd. | D- | 41/100 | — | — | -35.0% | +0.56% | $109.5M | /pypd-vs-apyx → |
| SKYA SkyAI Inc. | D- | 43/100 | — | -30.0% | -35.0% | -1.35% | $128.4M | /skya-vs-apyx → |
| LUNG Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | -14.14% | $129.1M | /lung-vs-apyx → |
| NYXH Nyxoah SA | D | 45/100 | — | — | — | +0.99% | $87.2M | /nyxh-vs-apyx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apyx Medical Corporation (APYX) reported GAAP revenue of $52.8M (+9.9% vs. FY2024 revenue of $48.1M , and +0.9% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$8.0M, and free cash flow of -$9.1M (+51.4% YoY). On the balance sheet, APYX closed FY2025 with $66.8M in total assets against $34.8M in total debt (Altman Z-Score: 0.75, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $52.8M | -$11.2M | -$8.0M | -$9.1M | $66.8M | $34.8M |
| FY2024 (FY) | 2024-12-31 | $48.1M | -$23.5M | -$18.0M | -$18.8M | $64.8M | $33.9M |
| FY2023 (FY) | 2023-12-31 | $52.3M | -$18.7M | -$5.2M | -$5.2M | — | — |
As of 2026-11-03, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.60 (0.00% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, APYX ranks #970 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
APYX last traded at $2.60 (0.00% on volume of 116,205 shares), positioning the stock -5.80% below its 50-day simple moving average ($2.76) and -27.58% below its 200-day simple moving average ($3.59). Across its 52-week range of $2.25 to $5.08, APYX sits at the 12.4% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.27 to $2.93).
Apyx Medical Corporation (APYX) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.60 (0.00% 1D, market capitalization $109.5M).
Apyx Medical Corporation (NASDAQ: APYX) is classified in the Health Care sector and the Medical/Dental Instruments industry .8M for FY 2025 indicates an operating business of meaningful scale.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Apyx Medical Corporation (APYX) reported $52.8M in annual revenue (up from $48.1M in FY2024, +9.9% YoY) and -$11.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($52.3M revenue, -$18.7M net income) through FY2025, APYX scaled operating cash flow to -$8.0M and free cash flow to -$9.1M, backed by $66.8M in total assets against $34.8M in total debt.
No upstream or downstream links are recorded and no proprietary signals are listed, so no supply-chain dependencies can be mapped from the source data. The sector classification (Health Care) and industry (Medical/Dental Instruments) are the only sector context provided. Sector correlation data is — An investor should watch the November 5, 2026 Q3 results as the first hard data point on whether the reported losses are narrowing, since the source data contains no supply-chain bottleneck information.
Real-time company headlines, analyst actions, and sector developments for Apyx Medical Corporation (APYX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Apyx Medical Corporation (APYX) market action, institutional positioning, and fundamental catalysts.
Long APYX at $2.60 targeting $3.43. Institutional accumulation and options positioning contribute 12/20 to the RQD score, the strongest pillar relative to the others.. Institutional whale score is 5/20 and the risk/reward vs. the $2.25 52-week low is skewed heavily in favor of bulls.
@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (62.5%) holds, EPS grows into the multiple faster than bears think.
Here is the bear case nobody on the bull side wants to address on APYX: ROIC of -28.9% and FCF yield of -8.04% leave the Fundamental Cash Engine at 4/20 with an Altman Z of 0.75.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: